Frequent Hemodialysis Network (FHN) randomized trials: Study design

Kidney International

Volumn 71, Issue 4, 2007, Pages 349-359

  Suri, R S ^a,i   Garg, A X ^a   Chertow, G M ^b   Levin, N W ^c   Rocco, M V ^d   Greene, T ^e   Beck, G J ^e   Gassman, J J ^e   Eggers, P W ^f   Star, R A ^f   Ornt, D B ^g   Kliger, A S ^h  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RENAL RESEARCH INSTITUTE   (United States)

^d WAKE FOREST BAPTIST HEALTH   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HOSPITAL OF SAINT RAPHAEL   (United States)

ⁱ LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Frequent hemodialysis; Left ventricular hypertrophy; Quality of life; Randomized controlled trials

Indexed keywords

SERUM ALBUMIN;

ADOLESCENT; ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD PRESSURE; DEATH; ERYTHROPOIESIS; FEASIBILITY STUDY; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PSYCHOLOGIC TEST; TREATMENT OUTCOME;

CLINICAL PROTOCOLS; DATA INTERPRETATION, STATISTICAL; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; QUALITY OF LIFE; RENAL DIALYSIS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 33846861959     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002032     Document Type: Article

References (43)

1. US Renal Data Systems. USRDS 2000 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda MD 2000.
2. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753-2758.
3. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis 2001; 38: 443-464.
4. Merkus MP, Jager KJ, Dekker FW et al. Quality of life over time in dialysis: the Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. Kidney Int 1999; 56: 720-728.
5. US Renal Data Systems. USRDS 2000 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.Bethesda MD 2000.
6. Canadian Organ Replacement Registry##2003. http://secure.cihi.ca/cihiweb/ dispPage.jsp?cw_page=statistics_results_topic_dialysis_e&cw_topic= Health%20Conditions&cw_subtopic=Dialysis (accessed August 2006).
7. Depner TA. Daily hemodialysis efficiency: an analysis of solute kinetics. Adv Ren Replace Ther 2001; 8: 227-235.
8. Gotch FA, Levin NW. Daily dialysis: the long and the short of it. Blood Purif 2003; 21: 271-281.
9. Suri RS, Nesrallah GE, Mainra R et al. Daily hemodialysis: a systematic review. Clin J Am Soc Nephrol 2006; 1: 33-42.
10. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 2005; 67: 1500-1508.
11. McFarlane PA. Reducing hemodialysis costs: conventional and quotidian home hemodialysis in Canada. Semin Dial 2004; 17: 118-124.
12. I. NKF-K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: update 2000. Am J Kidney Dis 2001; 37: S7-S64.
13. Mowatt G, Vale L, MacLeod A. Systematic review of the effectiveness of home versus hospital or satellite unit hemodialysis for people with end-stage renal failure. Int J Technol Assess Health Care 2004; 20: 258-268.
14. Woods JD, Port FK, Stannard D et al. Comparison of mortality with home hemodialysis and center hemodialysis: a national study. Kidney Int 1996; 49: 1464-1470.
15. Bliwise DL, Kutner NG, Zhang R, Parker KP. Survival by time of day of hemodialysis in an elderly cohort. JAMA 2001; 286: 2690-2694.
16. Quintaliani G, Buoncristiani U, Fagugli R et al. Survival of vascular access during daily and three times a week hemodialysis. Clin Nephrol 2000; 53: 372-377.
17. Woods JD, Port FK, Orzol S et al. Clinical and biochemical correlates of starting 'daily' hemodialysis. Kidney Int 1999; 55: 2467-2476.
18. Lindsay RM, Leitch R, Heidenheim AP, Kortas C. The London Daily/Nocturnal Hemodialysis Study - study design, morbidity, and mortality results. Am J Kidney Dis 2003; 42: 5-12.
19. Ting GO, Kjellstrand C, Freitas T et al. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 2003; 42: 1020-1035.
20. Kooistra MP, Vos PF. Daily home hemodialysis: towards a more physiological treatment of patients with ESRD. Semin Dial 1999; 12: 424-430.
21. Al Hejaili F, Kortas C, Leitch R et al. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol 2003; 14: 2322-2328.
22. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001; 33: 350-357.
23. DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 1997; 30: 204-212.
24. Mapes DL, Bragg-Gresham JL, Bommer J et al. Health-related quality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 54-60.
25. Lowrie EG, Curtin RB, LePain N, Schatell D. Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis 2004; 44: 54-60.
26. London GM, Pannier B, Guerin AP et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767.
27. Paoletti E, Specchia C, Di Maio G et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004; 19: 1829-1834.
28. Zoccali C, Benedetto FA, Mallamaci F et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65: 1492-1498.
29. Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. Am J Kidney Dis 2003; 42: 36-41.
30. Traeger J, Galland R, Delawari E et al. Six years' experience with short daily hemodialysis: do the early improvements persist in the mid and long term? Hemodial Int 2004; 8: 151-158.
31. Ayus JC, Mizani MR, Achinger SG et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16: 2778-2788.
32. Fagugli RM, Reboldi G, Quintaliani G et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 2001; 38: 371-376.
33. Chan CT, Floras JS, Miller JA et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002; 61: 2235-2239.
34. Hochberg YA. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-803.
35. Samsa G, Edelman D, Rothman ML et al. Determining clinically important differences in health status measures: a general approach with illustration to the health utilities index mark II. Pharmacoeconomics 1999; 15: 141-155.
36. Pett SL, Emery S. Immunomodulators as adjunctive therapy for HIV-1 infection. J Clin Virol 2001; 22: 289-295.
37. Cartmel B, Dziura J, Cullen MR et al. Changes in cholesterol and triglyceride concentrations in the Vanguard population of the Carotene and Retinol Efficacy Trial (CARET). Eur J Clin Nutr 2005; 59: 1173-1180.
38. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension 2002; 39: 750-755.
39. Stewart GA, Foster J, Cowan M et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 1999; 56: 2248-2253.
40. Fisch BJ, Spiegel DM. Assessment of excess fluid distribution in chronic hemodialysis patients using bioimpedance spectroscopy. Kidney Int 1996; 49: 1105-1109.
41. Guyatt G, Cook D, Devereaux PJ et al. Therapy. In Guyatt G, Rennie D (eds). Users' Guide To The Medical Literature. pp 55-79##Chicago: AMA Press, 2002.
42. McLaughlin K, Manns B, Mortis G et al. Why patients with ESRD do not select self-care dialysis as a treatment option. Am J Kidney Dis 2003; 41: 380-385.
43. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.